Reducing Safety-Related Drug Attrition- An Interview with Gareth Waldron
Safety-related drug attrition is obviously a huge problem in drug trials. How can companies work to reduce this? We spoke with Gareth Waldron Non-Clinical Safety Lead at Pfizer Neusentis about in vitro pharmacological profiling, how it could be implemented to reduce this attrition and the success stories so far.
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.